Differentiation of rhabdomyosarcoma cell lines using retinoic acid

Pediatric Blood and Cancer

Volumn 47, Issue 6, 2006, Pages 773-784

  Barlow, Jason W ^a   Wiley, Joe C ^b   Mous, Marieke ^c   Narendran, Aru ^b,e   Gee, Matthew F W ^a   Goldberg, Michael ^d   Sexsmith, Elizabeth ^b   Malkin, David ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF TORONTO   (Canada)

^e ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

Differentiation; MyoD; p53; Retinoic acid; Rhabdomyosarcoma

Indexed keywords

ALITRETINOIN; PROTEIN DERIVATIVE; RETINOIC ACID; TROPONIN T;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; CELL STRUCTURE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH CURVE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SEQUENCE ANALYSIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; ETHANOL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; RHABDOMYOSARCOMA; SENSITIVITY AND SPECIFICITY; TRETINOIN; TROPONIN T; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33749165729     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20650     Document Type: Article

References (43)

1. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23:215-220.
2. Dagher R, Helman L. Rhabdomyosarcoma: An overview. Oncologist 1999;4:34-44.
3. Koufos A, Hansen MF, Copeland NG, et al. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 1985;316:330-334.
4. Turc-Carel C, Lizard-Nacol S, Justrabo E, et al. Consistent chromosomal translocation in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 1986;19:361-362.
5. Biegel JA, Meek RS, Parmiter AH, et al. Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma. Genes Chrom Cancer 1991;3:483-484.
6. Douglass EC, Rowe ST, Valentine M, et al. Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. Genes Chrom Cancer 1991;3:480-482.
7. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to Pax3 in the solid tumor alveolar rhabdomyosarcoma. Nature Gen 1993;5:230-235.
8. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FOXO1A by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994;54:2869.
9. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol 2002;20:2672-2679.
10. Lassar AB, Buskin JN, Lockshon D, et al. MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer. Cell 1989;58:823-831.
11. Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 1993;259:1450-1453.
12. Maroto M, Reshef R, Munsterberg AE, et al. Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 1997;89:139-148.
13. Epstein JA, Lam P, Jepeal L, et al. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 1995;270:11719-11722.
14. Bernasconi M, Remppis A, Fredericks WJ, et al. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of Pax proteins. Proc Natl Acad Sci USA 1996;93:13164-13169.
15. Fredericks WJ, Galili N, Mukhopadhyay S, et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995;15:1522-1535.
16. Bennicelli JL, Advani S, Schafer BW, et al. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 1999;18:4348-4356.
17. Elliott S, Taylor K, White S, et al. Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 1992;79:1916-1919.
18. Ramp U, Gerharz C, Engers R, et al. Differentiation induction in the human rhabdomyosarcoma cell line TE-671. A morphological, biochemical and molecular analysis. Anticancer Res 1995;15:181-188.
19. Crouch GD, Helman LJ. All trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. Cancer Res 1991;51:4882-4887.
20. Garvin AJ, Stanley WS, Sullivan JL, et al. The in vitro growth, heterotransplantation, and differentiation of a human rhabdomyosarcoma cell line. Am J Pathol 1986;5:208-217.
21. Ogose A, Motoyama T, Hotta T, et al. In vitro differentiation and proliferation in a newly established human rhabdomyosarcoma cell line. Virchows Arch 1995;426:385-391.
22. Albagli-Curiel O, Carnac G, Vandromme M, et al. Serum-induced inhibition of myogenesis is differentially relieved by retinoic acid and triodothyronine in C2 murine muscle cells. Differentiation 1993;52:201-210.
23. Alric S, Froeschle A, Piquemal D, et al. Functional specificity of the two retinoic acid receptor RAR and RXR families in myogenesis. Oncogene 1998;16:273-282.
24. Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977;270:725-727.
25. Yaffe D. Retention of differentioation potentialities during prolonged cultivation of myogenic cells. Proc Natl Acad Sci USA 1968;61:477-483.
26. Mashiyama S, Murakami Y, Yoshimoto T, et al. Detection of p53 gene mutations in human brain tumours by single strand confirmation polymorphism analysis of polymerase chain reaction products. Oncogene 1991;6:1313-1318.
27. Peng HQ, Hogg D, Malkin D, et al. Mutations of the p53 gene do not occur in testis caner. Cancer Res 1993;53:3574-3578.
28. Soddu S, Blandino G, Scardigli R, et al. Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol 1996;134:193-204.
29. Diller L, Sexsmith E, Gottlieb A, et al. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995;95:1606-1611.
30. Tamir Y, Bengal E. p53 protein is activated during muscle differentiation and participates with MyoD in the transcription of muscle creatine kinase gene. Oncogene 1998;17:347-356.
31. Felix CA, Kappel CC, Mitsudomi T, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992;52:2243-2247.
32. Taylor AC, Shu L, Danks MK, et al. p53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncology 2000;35:96-103.
33. Fiddler TA, Smith L, Tapscott SJ, Thayer MJ. Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol Cell Biol 1996;16:5048-5057.
34. Kastner P, Mark M, Ghyselinck N, et al. Genetic evidence that the retinoid signal is transduced by heterodimeric RXR/RAR functional units during mouse development. Development 1997;124:313-326.
35. Alland L, Muhle R, Hou H Jr, et al. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 1997;387:49-55.
36. Heinzel T, Lavinsky RM, Mullen TM, et al. A complex containing N-CoR, mSin3, and histone deacetylase mediates transcriptional repression. Nature 1997;387:43-48.
37. Nagy L, Kao HY, Love JD, et al. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev 1999;13:3209-32016.
38. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14:121-141.
39. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-3215.
40. He LZ, Merghoub T, Pandolfi PP. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene 1999;18:5278-5292.
41. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216.
42. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 1998;18:126-135.
43. Coffey DC, Kutko MC, Glick RD, et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 2000;35:577-581.